Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium

Journal of Clinical Investigation

Volumn 119, Issue 9, 2009, Pages 2702-2713

  Lee, Daekee ^a,b   Yu, Ming ^a,c   Lee, Eunjung ^b   Kim, Hyunok ^b   Yang, Yanan ^d   Kim, Kyoungmi ^b   Pannicia, Christina ^a   Kurie, Jonathan M ^d   Threadgill, David W ^a,c,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Ewha Womans University   (South Korea)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERBB3 PROTEIN PSEUDO KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELL TRANSFORMATION; COLORECTAL CANCER; CONTROLLED STUDY; ERBB3 GENE; GENE; GENE EXPRESSION REGULATION; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CASPASE 3; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENES, APC; GENES, ERBB; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RNA, SMALL INTERFERING;

EID: 70349199083     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36435     Document Type: Article

References (44)

1. Hynes, N.E., and Lane, H.A. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer. 5:341-354. (Pubitemid 40637826)
2. Herbst, R.S., and Sandler, A.B. 2004. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin. Lung Cancer. 6(Suppl. 1):S7-S19.
3. Saltz, L.B. 2004. Palliative management of rectal cancer: the roles of chemotherapy and radiation therapy. J. Gastrointest. Surg. 8:274-276. (Pubitemid 38340604)
4. Rothenberg, M.L., et al. 2005. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol. 23:9265-9274.
5. Cunningham, M.P., Thomas, H., Fan, Z., and Modjtahedi, H. 2006. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res. 66:7708-7715. (Pubitemid 44289230)
6. Ponz-Sarvise, M., et al. 2007. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J. Gastroenterol. 13:5877-5887. (Pubitemid 350148504)
7. Fields, A.L.A., et al. 2005. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer [abstract]. In 2005 ASCO Annual Meeting Proceedings. Vol. 23, No. 16S (June 1 Supplement). J. Clin. Oncol. 23:3583.
8. Yarden, Y., and Sliwkowski, M.X. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137.
9. Guy, P.M., Platko, J.V., Cantley, L.C., Cerione, R.A., and Carraway, K.L., 3rd. 1994. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. U. S. A. 91:8132-8136.
10. Sierke, S.L., Cheng, K., Kim, H.H., and Koland, J.G. 1997. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 322:757-763. (Pubitemid 27135621)
11. Soltoff, S.P., Carraway, K.L., 3rd, Prigent, S.A., Gullick, W.G., and Cantley, L.C. 1994. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14:3550-3558.
12. Kim, H.H., Sierke, S.L., and Koland, J.G. 1994. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J. Biol. Chem. 269:24747-24755. (Pubitemid 24311732)
13. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., and Mills, G.B. 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4:988-1004.
14. Naidu, R., Yadav, M., Nair, S., and Kutty, M.K. 1998. Expression of c-erbB3 protein in primary breast carcinomas. Br. J. Cancer. 78:1385-1390. (Pubitemid 28495255)
15. Ciardiello, F., et al. 1991. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc. Natl. Acad. Sci. U. S. A. 88:7792-7796. (Pubitemid 21915240)
16. Maurer, C.A., et al. 1998. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum. Pathol. 29:771-777.
17. Kobayashi, M., Iwamatsu, A., Shinohara-Kanda, A., Ihara, S., and Fukui, Y. 2003. Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene. 22:1294-1301. (Pubitemid 36384590)
18. Rajkumar, T., Stamp, G.W., Hughes, C.M., and Gullick, W.J. 1996. c-erbB3 protein expression in ovarian cancer. Clin. Mol. Pathol. 49:M199-M202.
19. Friess, H., Guo, X.Z., Nan, B.C., Kleeff, O., and Buchler, M.W. 1999. Growth factors and cytokines in pancreatic carcinogenesis. Ann. N. Y. Acad. Sci. 880:110-121. (Pubitemid 29349119)
20. Holbro, T., et al. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 100:8933-8938. (Pubitemid 36899201)
21. Siegel, P.M., Ryan, E.D., Cardiff, R.D., and Muller, W.J. 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18:2149-2164.
22. Engelman, J.A., et al. 2005. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. U. S. A. 102:3788-3793.
23. Engelman, J.A., et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039-1043.
24. Erickson, S.L., et al. 1997. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 124:4999-5011.
25. Riethmacher, D., et al. 1997. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 389:725-730. (Pubitemid 27458958)
26. Wu, L., et al. 2003. Extra-embryonic function of Rb is essential for embryonic development and viability. Nature. 421:942-947. (Pubitemid 36288025)
27. Hayashi, S., Lewis, P., Pevny, L., and McMahon, A.P. 2002. Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain. Mech. Dev. 119:S97-S101. (Pubitemid 39658693)
28. Madison, B.B., et al. 2002. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 277:33275-33283.
29. Hellyer, N.J., Cheng, K., and Koland, J.G. 1998. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 333:757-763. (Pubitemid 28398546)
30. Prigent, S.A., and Gullick, W.J. 1994. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:2831-2841. (Pubitemid 24191693)
31. Cantley, L.C. 2002. The phosphoinositide 3-kinase pathway. Science. 296:1655-1657.
32. Chen, T., et al. 2003. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res. 63:4368-4374. (Pubitemid 36951005)
33. Roberts, R.B., et al. 2002. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 99:1521-1526.
34. Boudeau, J., Miranda-Saavedra, D., Barton, G.J., and Alessi, D.R. 2006. Emerging roles of pseudokinases. Trends Cell Biol. 16:443-452.
35. Xue, C., et al. 2006. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res. 66:192-197. (Pubitemid 43166025)
36. Lee, D., et al. 2004. Wa5 is a novel ENU-induced antimorphic allele of the epidermal growth factor receptor. Mamm. Genome. 15:525-536. (Pubitemid 38798843)
37. Schmelz, E.M., et al. 2007. Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein. Cancer Res. 67:5389-5396.
38. Asnaghi, L., et al. 2004. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene. 23:5781-5791. (Pubitemid 39093023)
39. Dignass, A.U., and Sturm, A. 2001. Peptide growth factors in the intestine. Eur. J. Gastroenterol. Hepatol. 13:763-770.
40. Moran, A.E., et al. 2004. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J. Biol. Chem. 279:43261-43272.
41. Schwartz, F., et al. 1991. A dominant positive and negative selectable gene for use in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 88:10416-10420. (Pubitemid 21915846)
42. Nagy, A., Gertsenstein, M., Vintersten, K., and Behringer, B. 2003. Manipulating the mouse embryo: a laboratory manual. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York, USA. 800 pp.
43. Lee, D., et al. 2004. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol. Cell. Biol. 24:8907-8916. (Pubitemid 39313896)
44. Kaiser, S., et al. 2007. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol. 8:R131. (Pubitemid 351916552)